Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades.  Sana is building differentiated capabilities across the spectrum of cell and gene therapy. 
 
Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body.  We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.
 
Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Over 8 million people worldwide are currently living with type 1 diabetes. At Sana, we’re advancing our hypoimmune platform for the potential treatment of this and other serious diseases. 

Check out The Economist article below highlighting promising preclinical diabetes data using our hypoimmune technology that were recently published in Cell Stem Cell.

https://lnkd.in/gRcYJtY9

Cancer prevention awareness is a key step towards a healthier future. Together, let's inspire change, promote healthy lifestyles, and drive advancements in cancer innovation to prevent and treat cancer. 

Learn more about cancer prevention here: https://lnkd.in/gT2vd6hZ

#CancerPrevention #BiotechInnovation #Cellengineering #CellTherapy

We are excited to share the publication of preclinical diabetes data in Cell Stem Cell. 
 
Published data demonstrate that transplantation of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells provided lasting glucose control, enabling the achievement of exogenous insulin independence without immunosuppression in a diabetic non-human primate (NHP). 
 
These data underscore the diverse and vast potential of the hypoimmune platform to transform the diabetes treatment landscape and beyond. 
 
Read more here: https://lnkd.in/g589pFsJ

Today we announced the closing of an upsized $189M public offering. 
 
We would like to recognize the tremendous support from healthcare investors, as well as the significant interest from scientific and healthcare communities, as we collectively work to change the possible for patients. 

Read more here: https://lnkd.in/gmX_ZVnV

At Sana, we recognize first-hand the vital role women play in driving innovation and shaping the future of science and medicine. 

We are committed to continuing to break barriers, inspire the next generation, and build a more inclusive and diverse scientific community. 

#WomenInScience #GirlsInScience #BiotechInnovation #STEMdiversity

Sana welcomes the Year of the Wood Dragon, a revered symbol in Chinese culture embodying growth, prosperity, and good fortune. 

We Look forward to a year filled with creativity, innovation, and abundant opportunities. #LunarNewYear

At Sana, our focus on changing the possible for patients through engineered cells is matched by our commitment to bring awareness to cancer prevention and early detection. 

Join us in fostering awareness, driving innovation, and uniting against cancer. Together, we can make strides in both treatment and prevention. 
 
#WorldCancerDay #CellTherapy #CancerPrevention #EarlyDetection

Sana will be honoring Black History Month throughout the month of February through various events within our community. 

The Sana Pledge is a commitment to ending inequality for all, and a meaningful part of our effort is directed toward countering racism and supporting the Black community.

"The future never just happened. It was created." -- Mae Jemison

#BlackHistoryMonth

We are honored for another feature in BioSpace’s annual Hotbed Maps, representing the most thriving life science regions across the country. With three primary office locations, Sana will be featured in the #BioForest, #BiotechBay, and #Genetown maps. 

In each of our locations, employees are relentless in discovering therapies that shift the possible for patients. 

Learn more about Sana, our culture, and open positions here: https://sana.com/join-us/

#hiring #jobsatSana

Today we memorialize the millions of lives lost and honor those who survived the acts of the Holocaust. We must stand united against hatred and intolerance, ensuring such atrocities never happen again.
 
#HolocaustRemembranceDay

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-130.78M -	-285.31M 118.16%	-355.93M 24.75%	-269.48M 24.29%	-283.25M 5.11%
depreciation and amortization	1.83M -	5.92M 224.26%	11.07M 86.96%	15.63M 41.15%	30.86M 97.54%
deferred income tax	-7.55M -				-96.24M -
stock based compensation	1.50M -	5.83M 289.31%	22.36M 283.70%	38.34M 71.44%	35.53M 7.31%
change in working capital	10.53M -	6.16M 41.52%	9.80M 59.21%	7.54M 23.05%	18.61M 146.76%
accounts receivables
inventory
accounts payables	-421K -	1.98M 570.78%	-266K 113.42%	1.06M 497.74%	1.03M 2.93%
other working capital	10.95M -	4.17M 61.87%	10.07M 141.18%	6.48M 35.59%	17.58M 171.19%
other non cash items	38.97M -	129.42M 232.08%	61.64M 52.37%	-82.08M 233.15%	40.90M 149.83%
net cash provided by operating activities	-85.50M -	-137.98M 61.37%	-251.05M 81.95%	-290.05M 15.53%	-253.58M 12.57%
investments in property plant and equipment	-26.18M -	-23.87M 8.83%	-29.86M 25.09%	-20.88M 30.09%	-20.03M 4.04%
acquisitions net	-3.19M -	228.69K 107.16%		-231.44K -
purchases of investments	-141.52M -	-387.43M 173.77%	-491.39M 26.83%	-78.69M 83.99%	-157.74M 100.47%
sales maturities of investments	82.98M -	158.74M 91.31%	280.02M 76.40%	310.13M 10.75%	349.79M 12.79%
other investing activites	59K -	-228.69K 487.61%	-4.57M 1,900.08%	231.44K 105.06%
net cash used for investing activites	-87.86M -	-252.56M 187.46%	-245.80M 2.68%	210.56M 185.66%	172.01M 18.31%
debt repayment
common stock issued	1K -	149K 14,800%	626.40M 420,306.04%	601K 99.90%	31.65M 5,165.56%
common stock repurchased
dividends paid
other financing activites	223.72M -	435.54M 94.68%	5.35M 98.77%	4.31M 19.34%
net cash used provided by financing activities	223.73M -	435.69M 94.74%	631.75M 45.00%	4.91M 99.22%	31.65M 544.13%
effect of forex changes on cash					4.41M -
net change in cash	50.36M -	45.14M 10.36%	134.90M 198.83%	-74.58M 155.28%	-45.52M 38.97%
cash at beginning of period	31.45M -	81.81M 160.15%	126.95M 55.18%	261.85M 106.26%	182.87M 30.16%
cash at end of period	81.81M -	126.95M 55.18%	261.85M 106.26%	187.27M 28.48%	137.35M 26.66%
operating cash flow	-85.50M -	-137.98M 61.37%	-251.05M 81.95%	-290.05M 15.53%	-253.58M 12.57%
capital expenditure	-26.18M -	-23.87M 8.83%	-29.86M 25.09%	-20.88M 30.09%	-20.03M 4.04%
free cash flow	-111.69M -	-161.85M 44.92%	-280.92M 73.56%	-310.93M 10.68%	-273.61M 12.00%

NASDAQ:SANA

Sana Biotechnology, Inc.

Last Close

6.05

26/07 20:00

Market Cap

1.15B

Beta: 0.62

Volume Today

1.34M

Avg: 1.19M

PE Ratio

−4.34

PFCF: −4.09

Preview